LIPOSYN 20%
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Oct 1981
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 8h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LIPOSYN 20% is an injectable lipid emulsion used for parenteral nutrition support in patients requiring intravenous nutritional therapy. It provides essential fatty acids and calories to patients unable to consume food orally or enterally. The product is a small-molecule lipid formulation administered intravenously.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30% intensity), signaling potential team contraction or redeployment to pipeline assets.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on LIPOSYN 20% offers limited growth trajectory given LOE approaching status and zero linked job postings, indicating the product team is either downsizing or consolidating roles. Career advancement is more likely through institutional/hospital accounts or cross-functional moves to growth-stage products within Abbott's portfolio.
Account Manager (Hospital/IDN)Product Manager
Worked on LIPOSYN 20% at Abbott? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.